What is Adherium?
Adherium Limited operates at the intersection of medical device manufacturing and digital health data management. The company is best known for its Hailie Smartinhaler technology, a sophisticated hardware-software ecosystem designed to track and optimize medication adherence. By integrating remote monitoring capabilities with cloud-based analytics, Adherium provides physicians, payers, and healthcare providers with actionable insights that mitigate the high costs associated with non-adherence. Their market position is defined by a commitment to evidence-based respiratory care, leveraging telehealth advancements to bridge the gap between clinical prescription and patient behavior in real-time.
How much funding has Adherium raised?
Adherium has raised a total of $44.9M across 8 funding rounds:
Stock Offering
$25.6M
Corporate Investment
$3M
Share Placement
$5.9M
Debt
$1.8M
Debt
$1.2M
Private Equity
$3.5M
Debt
$3M
Other Financing Round
$900K
Stock Issuance/Offering (2015): $25.6M with participation from Undisclosed
Corporate Investment (2015): $3M led by AstraZeneca
Share Placement (2016): $5.9M supported by Fidelity
Debt (2019): $1.8M featuring Summatix Pty Limited and One Funds Management Limited
Debt (2019): $1.2M backed by Trudell Medical Limited
Private Equity (2020): $3.5M with participation from Undisclosed
Debt (2020): $3M led by Viburnum
Other Financing Round (2025): $900K supported by Trudell Medical and Phillips Asset Management
Key Investors in Adherium
AstraZeneca
A global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines across multiple therapeutic areas including respiratory and immunology.
Trudell Medical
A specialized manufacturer of respiratory care devices, including the AeroChamber and Aerobika brands, dedicated to improving patient outcomes through innovative medical technology.
Fidelity
A diversified financial services firm providing comprehensive investment, wealth management, and advisory solutions to institutional and individual clients globally.
What's next for Adherium?
Looking ahead, Adherium is well-positioned to capitalize on the increasing global demand for remote patient monitoring and virtual care pathways. With the support of its strategic partners, the company is likely to focus on deepening its integration within existing healthcare provider workflows and expanding its footprint in international markets. The strategic focus will likely shift toward enhancing the predictive capabilities of its data platform, ensuring that the Hailie ecosystem remains the gold standard for respiratory management. As the industry moves toward value-based care models, Adherium's ability to demonstrate measurable reductions in healthcare utilization will be a key driver of its long-term enterprise value and market penetration.
See full Adherium company page
